U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C24H32O6
Molecular Weight 416.5073
Optical Activity UNSPECIFIED
Defined Stereocenters 8 / 8
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of DESONIDE

SMILES

[H][C@@]12C[C@@]3([H])[C@]4([H])CCC5=CC(=O)C=C[C@]5(C)[C@@]4([H])[C@@H](O)C[C@]3(C)[C@@]1(OC(C)(C)O2)C(=O)CO

InChI

InChIKey=WBGKWQHBNHJJPZ-LECWWXJVSA-N
InChI=1S/C24H32O6/c1-21(2)29-19-10-16-15-6-5-13-9-14(26)7-8-22(13,3)20(15)17(27)11-23(16,4)24(19,30-21)18(28)12-25/h7-9,15-17,19-20,25,27H,5-6,10-12H2,1-4H3/t15-,16-,17-,19+,20+,22-,23-,24+/m0/s1

HIDE SMILES / InChI

Molecular Formula C24H32O6
Molecular Weight 416.5073
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 7 / 8
E/Z Centers 0
Optical Activity UNSPECIFIED

Desonide is a topical glucocorticoid which was approved by FDA for the treatment of such conditions as eczema, psoriasis, atopic dermatitis, etc. The exact mechanism of drug action is unknown.

Approval Year

Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
DESONIDE

Approved Use

Desonide Ointment, 0.05% is a low potency corticosteroid indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid responsive dermatoses. It should not be used for longer than two weeks unless directed by a physician.

Launch Date

6.3331201E10
Primary
DESONIDE

Approved Use

Desonide Cream, 0.05% is a low potency corticosteroid indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid responsive dermatoses.

Launch Date

6.3331201E10
Primary
DESONIDE

Approved Use

Desonide Cream, 0.05% is a low potency corticosteroid indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid responsive dermatoses.

Launch Date

6.3331201E10
Primary
DESONIDE

Approved Use

Desonide Cream, 0.05% is a low potency corticosteroid indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid responsive dermatoses.

Launch Date

6.3331201E10
Primary
DESONIDE

Approved Use

Desonide Cream, 0.05% is a low potency corticosteroid indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid responsive dermatoses.

Launch Date

6.3331201E10
Doses

Doses

DosePopulationAdverse events​
0.05 % 2 times / day multiple, topical
Recommended
Dose: 0.05 %, 2 times / day
Route: topical
Route: multiple
Dose: 0.05 %, 2 times / day
Sources: Page: p.3
unhealthy
n = 425
Health Status: unhealthy
Condition: Atopic dermatitis
Population Size: 425
Sources: Page: p.3
Disc. AE: Telangiectasia...
AEs leading to
discontinuation/dose reduction:
Telangiectasia
Sources: Page: p.3
0.05 % 2 times / day multiple, topical
Recommended
Dose: 0.05 %, 2 times / day
Route: topical
Route: multiple
Dose: 0.05 %, 2 times / day
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Atopic dermatitis
Sources: Page: p.1
Disc. AE: Cushing's syndrome, Hypothalamic pituitary adrenal axis suppression...
AEs leading to
discontinuation/dose reduction:
Cushing's syndrome
Hypothalamic pituitary adrenal axis suppression
Atrophy
Striae
Irritation skin
Acneiform eruption
Skin hypopigmentation
Allergic contact dermatitis
Sources: Page: p.1
AEs

AEs

AESignificanceDosePopulation
Telangiectasia Disc. AE
0.05 % 2 times / day multiple, topical
Recommended
Dose: 0.05 %, 2 times / day
Route: topical
Route: multiple
Dose: 0.05 %, 2 times / day
Sources: Page: p.3
unhealthy
n = 425
Health Status: unhealthy
Condition: Atopic dermatitis
Population Size: 425
Sources: Page: p.3
Acneiform eruption Disc. AE
0.05 % 2 times / day multiple, topical
Recommended
Dose: 0.05 %, 2 times / day
Route: topical
Route: multiple
Dose: 0.05 %, 2 times / day
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Atopic dermatitis
Sources: Page: p.1
Allergic contact dermatitis Disc. AE
0.05 % 2 times / day multiple, topical
Recommended
Dose: 0.05 %, 2 times / day
Route: topical
Route: multiple
Dose: 0.05 %, 2 times / day
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Atopic dermatitis
Sources: Page: p.1
Atrophy Disc. AE
0.05 % 2 times / day multiple, topical
Recommended
Dose: 0.05 %, 2 times / day
Route: topical
Route: multiple
Dose: 0.05 %, 2 times / day
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Atopic dermatitis
Sources: Page: p.1
Cushing's syndrome Disc. AE
0.05 % 2 times / day multiple, topical
Recommended
Dose: 0.05 %, 2 times / day
Route: topical
Route: multiple
Dose: 0.05 %, 2 times / day
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Atopic dermatitis
Sources: Page: p.1
Hypothalamic pituitary adrenal axis suppression Disc. AE
0.05 % 2 times / day multiple, topical
Recommended
Dose: 0.05 %, 2 times / day
Route: topical
Route: multiple
Dose: 0.05 %, 2 times / day
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Atopic dermatitis
Sources: Page: p.1
Irritation skin Disc. AE
0.05 % 2 times / day multiple, topical
Recommended
Dose: 0.05 %, 2 times / day
Route: topical
Route: multiple
Dose: 0.05 %, 2 times / day
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Atopic dermatitis
Sources: Page: p.1
Skin hypopigmentation Disc. AE
0.05 % 2 times / day multiple, topical
Recommended
Dose: 0.05 %, 2 times / day
Route: topical
Route: multiple
Dose: 0.05 %, 2 times / day
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Atopic dermatitis
Sources: Page: p.1
Striae Disc. AE
0.05 % 2 times / day multiple, topical
Recommended
Dose: 0.05 %, 2 times / day
Route: topical
Route: multiple
Dose: 0.05 %, 2 times / day
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Atopic dermatitis
Sources: Page: p.1
Overview

Overview

CYP3A4CYP2C9CYP2D6hERG

OverviewOther

Other InhibitorOther SubstrateOther Inducer
Drug as victim

Drug as victim

TargetModalityActivityMetaboliteClinical evidence
yes
yes (co-administration study)
Comment: Concomitant oral administration of ketoconazole (a known inhibitor of CYP3A4 activity in the liver and in the intestinal mucosa) caused an eight-fold increase of the systemic exposure to oral budesonide. If treatment with inhibitors of CYP3A4 activity (such as ketoconazole, intraconazole, ritonavir, indinavir, saquinavir, erythromycin, etc.) is indicated, reduction of the budesonide dose should be considered
Page: 4,8
PubMed

PubMed

TitleDatePubMed
Clinical comparison of alclometasone dipropionate and desonide ointments (0.05%) in the management of psoriasis.
1982
Allergic contact dermatitis from topical corticosteroids.
1989 Aug
A double-blind placebo-controlled study of ketoconazole + desonide gel combination in the treatment of facial seborrheic dermatitis.
2002
Evaluation of cross-reactivity between budesonide and desonide.
2002 Aug
Efficacy, cutaneous tolerance and cosmetic acceptability of desonide 0.05% lotion (Desowen) versus vehicle in the short-term treatment of facial atopic or seborrhoeic dermatitis.
2002 Aug
[Connubial contact dermatitis to an inhaled corticosteroid].
2005 Feb
Comparison of the analysis of corticosteroids using different techniques.
2005 Jan
Erythematous scaling eyelids: patient history, exposure to allergens and irritants are keys to diagnosis.
2005 Jun
Corneofungimetry bioassay on Malassezia spp. under ketoconazole and desonide influences.
2005 Mar-Apr
Rapid resolution of a common problem.
2005 May
Photochemistry of desonide, a non-fluorinated steroidal anti-inflammatory drug.
2006 Jun
Verdeso (desonide) Foam, 0.05%.
2007 Jan-Feb
Periorbital cutaneous neonatal lupus.
2007 May-Jun
Tega-dermabrasion.
2007 Sep
Desonide gel.
2007 Sep-Oct
New and emerging trends in the treatment of atopic dermatitis.
2008 Feb 2
Inflammation of actinic keratosis with combination of alkylating and taxane agents: a case report.
2009 Jul 2
Manifestations of cutaneous sarcoidosis: a case report of an African American woman.
2009 Jun
Drugs associated with more suicidal ideations are also associated with more suicide attempts.
2009 Oct 2
Lenalidomide-induced acute acneiform folliculitis of the head and neck: not only the anti-EGF receptor agents.
2010
Good adherence and early efficacy using desonide hydrogel for atopic dermatitis: results from a program addressing patient compliance.
2010 Apr
Generic sample preparation combined with high-resolution liquid chromatography-time-of-flight mass spectrometry for unification of urine screening in doping-control laboratories.
2010 Apr
Pediatric atopic dermatitis: a review of the medical management.
2010 Sep
Patents

Sample Use Guides

Desonide Cream, 0.05% should be applied to the affected area as a thin film two to four times daily depending on the severity of the condition.
Route of Administration: Topical
In Vitro Use Guide
Unknown
Substance Class Chemical
Created
by admin
on Wed Jul 05 22:45:14 UTC 2023
Edited
by admin
on Wed Jul 05 22:45:14 UTC 2023
Record UNII
J280872D1O
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
DESONIDE
INN   MART.   MI   ORANGE BOOK   USAN   USP-RS   VANDF   WHO-DD  
USAN   INN  
Official Name English
DESONIDE [MART.]
Common Name English
DESONIDE COMPONENT OF TRIDESILON
Common Name English
DESONIDE [ORANGE BOOK]
Common Name English
TRIDESILON COMPONENT DESONIDE
Common Name English
DESONIDE [USP IMPURITY]
Common Name English
DESONIDE [USAN]
Common Name English
DESONIDE [USP MONOGRAPH]
Common Name English
PREGNA-1,4-DIENE-3,20-DIONE, 11,21-DIHYDROXY-16,17-((1-METHYLETHYLIDENE)BIS(OXY))-, (11.BETA.,16.ALPHA.)-
Common Name English
VERDESO
Brand Name English
11β,16α,17,21-Tetrahydroxypregna-1,4-diene-3,20-dione cyclic 16,17-acetal with acetone
Common Name English
BUDESONIDE IMPURITY F [EP IMPURITY]
Common Name English
DESOWEN
Brand Name English
DESONIDE [USP-RS]
Common Name English
D-2083
Code English
DESONIDE [VANDF]
Common Name English
D2083
Code English
desonide [INN]
Common Name English
NSC-759226
Code English
Desonide [WHO-DD]
Common Name English
DESONIDE [MI]
Common Name English
DESONATE
Brand Name English
Classification Tree Code System Code
WHO-ATC S01BA11
Created by admin on Wed Jul 05 22:45:14 UTC 2023 , Edited by admin on Wed Jul 05 22:45:14 UTC 2023
NDF-RT N0000175450
Created by admin on Wed Jul 05 22:45:14 UTC 2023 , Edited by admin on Wed Jul 05 22:45:14 UTC 2023
WHO-VATC QS01BA11
Created by admin on Wed Jul 05 22:45:14 UTC 2023 , Edited by admin on Wed Jul 05 22:45:14 UTC 2023
WHO-ATC D07BB02
Created by admin on Wed Jul 05 22:45:14 UTC 2023 , Edited by admin on Wed Jul 05 22:45:14 UTC 2023
WHO-VATC QD07BB02
Created by admin on Wed Jul 05 22:45:14 UTC 2023 , Edited by admin on Wed Jul 05 22:45:14 UTC 2023
WHO-ATC D07AB08
Created by admin on Wed Jul 05 22:45:14 UTC 2023 , Edited by admin on Wed Jul 05 22:45:14 UTC 2023
WHO-VATC QD07AB08
Created by admin on Wed Jul 05 22:45:14 UTC 2023 , Edited by admin on Wed Jul 05 22:45:14 UTC 2023
NDF-RT N0000175576
Created by admin on Wed Jul 05 22:45:14 UTC 2023 , Edited by admin on Wed Jul 05 22:45:14 UTC 2023
NCI_THESAURUS C521
Created by admin on Wed Jul 05 22:45:14 UTC 2023 , Edited by admin on Wed Jul 05 22:45:14 UTC 2023
Code System Code Type Description
EPA CompTox
DTXSID7046756
Created by admin on Wed Jul 05 22:45:14 UTC 2023 , Edited by admin on Wed Jul 05 22:45:14 UTC 2023
PRIMARY
CAS
638-94-8
Created by admin on Wed Jul 05 22:45:14 UTC 2023 , Edited by admin on Wed Jul 05 22:45:14 UTC 2023
PRIMARY
ChEMBL
CHEMBL1201109
Created by admin on Wed Jul 05 22:45:14 UTC 2023 , Edited by admin on Wed Jul 05 22:45:14 UTC 2023
PRIMARY
IUPHAR
7066
Created by admin on Wed Jul 05 22:45:14 UTC 2023 , Edited by admin on Wed Jul 05 22:45:14 UTC 2023
PRIMARY
CHEBI
204734
Created by admin on Wed Jul 05 22:45:14 UTC 2023 , Edited by admin on Wed Jul 05 22:45:14 UTC 2023
PRIMARY
WIKIPEDIA
DESONIDE
Created by admin on Wed Jul 05 22:45:14 UTC 2023 , Edited by admin on Wed Jul 05 22:45:14 UTC 2023
PRIMARY
DRUG CENTRAL
3135
Created by admin on Wed Jul 05 22:45:14 UTC 2023 , Edited by admin on Wed Jul 05 22:45:14 UTC 2023
PRIMARY
INN
2889
Created by admin on Wed Jul 05 22:45:14 UTC 2023 , Edited by admin on Wed Jul 05 22:45:14 UTC 2023
PRIMARY
DRUG BANK
DB01260
Created by admin on Wed Jul 05 22:45:14 UTC 2023 , Edited by admin on Wed Jul 05 22:45:14 UTC 2023
PRIMARY
ECHA (EC/EINECS)
211-351-6
Created by admin on Wed Jul 05 22:45:14 UTC 2023 , Edited by admin on Wed Jul 05 22:45:14 UTC 2023
PRIMARY
LACTMED
Desonide
Created by admin on Wed Jul 05 22:45:14 UTC 2023 , Edited by admin on Wed Jul 05 22:45:14 UTC 2023
PRIMARY
PUBCHEM
5311066
Created by admin on Wed Jul 05 22:45:14 UTC 2023 , Edited by admin on Wed Jul 05 22:45:14 UTC 2023
PRIMARY
MESH
D003898
Created by admin on Wed Jul 05 22:45:14 UTC 2023 , Edited by admin on Wed Jul 05 22:45:14 UTC 2023
PRIMARY
RS_ITEM_NUM
1173304
Created by admin on Wed Jul 05 22:45:14 UTC 2023 , Edited by admin on Wed Jul 05 22:45:14 UTC 2023
PRIMARY
EVMPD
SUB07005MIG
Created by admin on Wed Jul 05 22:45:14 UTC 2023 , Edited by admin on Wed Jul 05 22:45:14 UTC 2023
PRIMARY
SMS_ID
100000083192
Created by admin on Wed Jul 05 22:45:14 UTC 2023 , Edited by admin on Wed Jul 05 22:45:14 UTC 2023
PRIMARY
RXCUI
3254
Created by admin on Wed Jul 05 22:45:14 UTC 2023 , Edited by admin on Wed Jul 05 22:45:14 UTC 2023
PRIMARY RxNorm
FDA UNII
J280872D1O
Created by admin on Wed Jul 05 22:45:14 UTC 2023 , Edited by admin on Wed Jul 05 22:45:14 UTC 2023
PRIMARY
NCI_THESAURUS
C61702
Created by admin on Wed Jul 05 22:45:14 UTC 2023 , Edited by admin on Wed Jul 05 22:45:14 UTC 2023
PRIMARY
MERCK INDEX
M4199
Created by admin on Wed Jul 05 22:45:14 UTC 2023 , Edited by admin on Wed Jul 05 22:45:14 UTC 2023
PRIMARY Merck Index
DAILYMED
J280872D1O
Created by admin on Wed Jul 05 22:45:14 UTC 2023 , Edited by admin on Wed Jul 05 22:45:14 UTC 2023
PRIMARY
NSC
759226
Created by admin on Wed Jul 05 22:45:14 UTC 2023 , Edited by admin on Wed Jul 05 22:45:14 UTC 2023
PRIMARY
Related Record Type Details
PARENT -> IMPURITY
This impurity is to be reported under total unspecified impurities. Do not report it under total specified impurities.
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
PARENT -> IMPURITY
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
Related Record Type Details
ACTIVE MOIETY